RT Journal Article
T1 A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
A1 Martínez-Cuadrón, David
A1 Gil, Cristina
A1 Serrano, Josefina
A1 Rodríguez, Gabriela
A1 Pérez-Oteyza, Jaime
A1 García-Boyero, Raimundo
A1 Jiménez-Bravo, Santiago
A1 Vives, Susana
A1 Vidriales, María Belén
A1 Lavilla, Esperanza
A1 Pérez-Simón, José A
A1 Tormo, Mar
A1 Colorado, Mercedes
A1 Bergua, Juan
A1 López, Juan A
A1 Herrera, Pilar
A1 Hernández-Campo, Pilar
A1 Gorrochategui, Julián
A1 Primo, Daniel
A1 Rojas, Jose Luis
A1 Villoria, Jesús
A1 Moscardó, Federico
A1 Troconiz, Iñaki
A1 Linares Gómez, María
A1 Martínez-López, Joaquín
A1 Ballesteros, Joan
A1 Sanz, Miguel
A1 Montesinos, Pau
A1 Spanish PETHEMA group, 
K1 Acute myeloid leukemia
K1 Clinical correlation
K1 Complete remission
K1 Ex vivo assay
K1 Pharmacological profile
AB Complete remission (CR) after induction therapy is the first treatment goal in acute myeloid leukemia (AML) patients and has prognostic impact. Our purpose is to determine the correlation between the observed CR/CRi rate after idarubicin (IDA) and cytarabine (CYT) 3 + 7 induction and the leukemic chemosensitivity measured by an ex vivo test of drug activity. Bone marrow samples from adult patients with newly diagnosed AML were included in this study. Whole bone marrow samples were incubated for 48 h in well plates containing IDA, CYT, or their combination. Pharmacological response parameters were estimated using population pharmacodynamic models. Patients attaining a CR/CRi with up to two induction cycles of 3 + 7 were classified as responders and the remaining as resistant. A total of 123 patients fulfilled the inclusion criteria and were evaluable for correlation analyses. The strongest clinical predictors were the area under the curve of the concentration response curves of CYT and IDA. The overall accuracy achieved using MaxSpSe criteria to define positivity was 81%, predicting better responder (93%) than non-responder patients (60%). The ex vivo test provides better yet similar information than cytogenetics, but can be provided before treatment representing a valuable in-time addition. After validation in an external cohort, this novel ex vivo test could be useful to select AML patients for 3 + 7 regimen vs. alternative schedules.
YR 2018
FD 2018-11-13
LK http://hdl.handle.net/10668/13223
UL http://hdl.handle.net/10668/13223
LA en
DS RISalud
RD Apr 15, 2025